Leukemia/Leukaemia: An Overview of Introduction, Types, Pathog

Introduction

Table of Contents

Leukemia (also spelled leukaemia) is a group of malignant hematological cancers originating in the bone marrow, characterized by the rapid, uncontrolled proliferation of abnormal, non-functional white blood cells (leukocytes). As these malignant cells accumulate, they crowd out healthy red blood cells, functional white blood cells, and platelets. This leads to bone marrow failure and severe systemic cytopenias.

Classification and Types

Leukemia is classified broadly by two parameters: progression speed (acute vs. chronic) and the cell lineage affected (myeloid vs. lymphoid). According to harmonized clinical frameworks, there are four primary types:

Acute Lymphoblastic Leukemia (ALL): Rapidly progressing; involves immature lymphoblasts. It is the most common childhood leukemia.
Acute Myeloid Leukemia (AML): Rapidly progressing; involves immature myeloblasts. It is the most common acute leukemia in adults.
Chronic Lymphocytic Leukemia (CLL): Slow-growing; involves partially mature but dysfunctional B or T lymphocytes. It predominantly affects older adults.
Chronic Myeloid Leukemia (CML): Slow-growing; characterized by the uncontrolled expansion of the myeloid granulocytic lineage. It is classically driven by a specific genetic translocation.

Pathogenesis

The root cause of leukemia is the acquisition of somatic DNA mutations and chromosomal alterations within hematopoietic stem or progenitor cells.

Genetic Alterations: Key mutations involve chromosomal translocations (such as the Philadelphia chromosome t (9;22) creating the BCR: ABL1 oncogene in CML), deletions, or specific gene mutations like FLT3, NPM1, and KMT2A.
Clonal Expansion: The mutated stem cell loses its capacity for normal terminal differentiation but gains enhanced self-renewal properties, resisting programmed cell death (apoptosis).
Bone Marrow Suppression: Proliferating clone “blasts” fill the bone marrow cavities, depleting normal hematopoietic niches. This causes:
- Anemia (lack of RBCs) – fatigue, pallor
- Thrombocytopenia (lack of platelets)- bruising, petechiae, bleeding
- Leukopenia/Granulocytopenia (lack of working WBCs) -recurrent, severe infections
Extramedullary Infiltration: Malignant cells escape into the peripheral blood, infiltrating tissues like the spleen, liver (hepatosplenomegaly), and lymph nodes (lymphadenopathy).

Laboratory Diagnosis

Accurate diagnostic confirmation relies on a multimodal laboratory approach:

Complete Blood Count (CBC): Reveals marked leukocytosis (or sometimes leukopenia), concurrent anemia, and thrombocytopenia.
Peripheral Blood Smear (PBS): Microscopic analysis reveals the presence of circulating immature blast cells. The observation of Auer rods in the cell cytoplasm strongly confirms AML.
Bone Marrow Aspirate & Biopsy: The definitive gold standard test. Acute leukemia requires a threshold of \(\ge \) 20% blasts in the marrow under traditional criteria.
Flow Cytometry (Immunophenotyping): Uses specific cell surface clusters of differentiation (CD markers) to differentiate myeloid lineages from T-cell or B-cell lymphoid lineages.
Cytogenetics & Molecular Diagnostics: Uses Karyotyping and Fluorescent in Situ Hybridization (FISH) to identify critical translocations. Next-Generation Sequencing (NGS) identifies specific mutations to guide targeted therapies.

Treatment Options

Leukemia management has transitioned heavily from traditional therapies into precise, personalized medical models:

Chemotherapy: The historic foundation. Acute variants often utilize systemic induction regimens (e.g., the classic “7+3” protocol for AML) followed by consolidation therapy.
Targeted Precision Medicine: Specific inhibitors attack the genetic weak points of the cancer cells.
- Tyrosine Kinase Inhibitors (TKIs): Drugs like Imatinib target BCR: ABL1 in CML.
- FLT3 Inhibitors: Quizartinib is utilized for mutational AML.
- Menin Inhibitors: New therapies like Revumenib target KMT2A or NPM1 mutated leukemias.
- BCL-2 Inhibitors: Venetoclax combinations are standard for older adults unable to tolerate intensive induction chemotherapy.
Immunotherapy & Cellular Therapy: Monoclonal antibodies, bispecific T-cell engagers (BiTEs), and CAR-T cell therapies modify patient immune responses to target surface markers like CD19 in ALL.
Stem Cell Transplantation (Allogeneic HSCT): Replaces a patient’s destroyed bone marrow with healthy donor stem cells to rebuild a cancer-free blood-forming system.

Prevention

Because most leukemias originate from spontaneous, non-inherited somatic mutations, there is no definitive preventive method. However, risk reduction involves avoiding known environmental and occupational triggers:

Minimizing long-term occupational exposure to volatile chemicals like benzene.
Avoiding unnecessary or unshielded exposure to ionizing radiation.
Implementing tobacco cessation programs to eliminate chemical carcinogens from smoking.
Strict clinical monitoring for secondary leukemias in patients undergoing specific prior chemotherapies or radiation for unrelated cancers.

Keynotes

Acute vs. Chronic: Acute forms affect primitive stem-like blast cells and kill rapidly if untreated; chronic forms affect more mature leukocytes and progress slowly over years.
Age Demographics: ALL is primarily a childhood disease with high cure rates. AML and CLL are predominantly found in older adult populations.
The Philadelphia Chromosome: The t (9;22) translocation transformed CML from a fatal disease into a manageable, chronic condition thanks to modern TKI therapies.
MRD Tracking: Measurable Residual Disease (MRD) monitoring using molecular PCR assays evaluates deep therapeutic responses to predict or prevent early relapses.

Leukemia/Leukaemia: An Overview of Introduction, Types, Pathogenesis,Lab Diagnosis, Treatment, Prevention, and Keynotes